Profile data is unavailable for this security.
About the company
Guizhou Sanli Pharmaceutical Co Ltd is a company mainly engaged in the research and development, production and sales of Chinese patent medicines. The Company's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The Company mainly sells its products through specialized academic marketing.
- Revenue in CNY (TTM)2.11bn
- Net income in CNY328.87m
- Incorporated1995
- Employees2.28k
- LocationGuizhou Sanli Pharmaceutical Co LtdXiayun Industrial Park, Pingba DistrictGUIYANG 550014ChinaCHN
- Phone+86 85 184607358
- Fax+86 85 138113572
- Websitehttps://www.gz-sanli.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Haixin Group Co Ltd | 841.27m | 178.76m | 5.40bn | 760.00 | 40.32 | 1.65 | -- | 6.42 | 0.1481 | 0.1481 | 0.697 | 3.62 | 0.1607 | 5.09 | 6.89 | 1,106,933.00 | 4.06 | 2.68 | 4.52 | 3.06 | 52.44 | 44.55 | 25.25 | 11.17 | 3.01 | -- | 0.0077 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.76bn | 272.96m | 5.42bn | 1.69k | 19.78 | 3.40 | -- | 3.08 | 0.6244 | 0.6244 | 4.05 | 3.63 | 0.5513 | 1.43 | 6.70 | 1,044,835.00 | 8.34 | 5.39 | 14.83 | 9.37 | 69.28 | 66.91 | 15.12 | 8.95 | 0.4736 | -- | 0.3161 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Guizhou Sanli Pharmaceutical Co Ltd | 2.11bn | 328.87m | 5.79bn | 2.28k | 18.13 | 3.62 | -- | 2.74 | 0.7798 | 0.7798 | 5.05 | 3.91 | 0.8372 | 2.90 | 4.48 | 925,761.20 | 13.32 | 12.39 | 19.88 | 16.72 | 69.37 | 70.45 | 15.91 | 16.31 | 1.62 | -- | 0.2373 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.31bn | 249.88m | 6.20bn | 1.40k | 24.59 | 2.31 | -- | 4.74 | 1.43 | 1.43 | 7.47 | 15.16 | 0.3941 | 1.83 | 6.97 | 933,769.90 | 7.53 | 8.72 | 9.23 | 10.64 | 75.76 | 85.10 | 19.11 | 19.16 | 2.65 | -- | 0.0717 | 26.80 | -4.56 | 7.76 | -8.09 | 10.91 | 17.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| HFT Investment Management Co., Ltd.as of 30 Sep 2023 | 3.57m | 0.88% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2024 | 2.70m | 0.66% |
| China International Capital Corp. HK Asset Management Ltd.as of 30 Jun 2024 | 2.19m | 0.54% |
| Hotland Innovation Asset Management Co. Ltd.as of 30 Jun 2024 | 1.79m | 0.44% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 1.37m | 0.34% |
| Peng Yang Amc Fund Management Co. Ltd.as of 30 Jun 2024 | 1.27m | 0.31% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 1.01m | 0.25% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 1.00m | 0.25% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 868.30k | 0.21% |
| Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2024 | 810.60k | 0.20% |
